Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
semaglutide
Biotech
Lilly's oral GLP-1 delivers Ozempic-like efficacy in phase 3
The phase 3 study linked the oral GLP-1 drug orforglipron to similar reductions in blood glucose and body weight to Novo's injectable blockbuster.
Nick Paul Taylor
Apr 17, 2025 6:45am
Novo links CagriSema to 16% weight loss, sending stock down
Mar 10, 2025 9:30am
Novo stock crashes after CagriSema misses weight-loss goal
Dec 20, 2024 8:15am
Macrocyclic peptides preserve muscle in mice given semaglutide
Dec 12, 2024 12:45pm
Biolexis enters small molecule into oral GLP-1 horse race
Sep 13, 2024 12:24pm
Terns' ex-MASH drug cuts fat, not muscle in GLP-1 combo in mice
Jun 25, 2024 8:51am
